In patients with bortezomib resistance, TG2 signaling can be inhibited by a calcium blocker such as perillyl alcohol and administered in combination with bortezomib to suppress NF-κB expression and improve MCL cell sensitivity to bortezomib [51]. This evidence concerns the gene NFKB1 and mantle cell lymphoma.